DMO: Study finds faricimab provides sustained retinal stability

In a study, outlined at the American Academy of Ophthalmology 2021 annual meeting in New Orleans, Dr Veeral Sheth and colleagues reported that faricimab, a bispecific monoclonal antibody, provided sustained retinal stability in patients with diabetic macular oedema (DMO) compared with other retinal treatments.

In preclinical studies, blocking angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A) reduced the vascular leakage/neovascularization, inflammation, and fibrosis.

In a phase 2 post hoc analyses, the investigators assessed, in the intention-to-treat population, the sustained retinal stability, defined as occurrence and less than 10% worsening of the central subfield to 325 microns or less to week 24. The inflammatory biomarker, intercellular adhesion molecule-1 (ICAM-1), levels also were assessed in a patient subset from baseline to week 28.

The investigators reported that more than 50% of patients achieved sustained retinal stability at weeks 8 and 16 with faricimab compared with week 20 with ranibizumab (Lucentis, Genentech). At week 28, the mean percentage of the ICAM-1 levels compared with baseline increased by 50% with ranibizumab and decreased by 56% and 42% in the 2 faricimab arms.

The investigators concluded that faricimab resulted in sustained retinal stability and ICAM-1 reduction compared with ranibizumab in the phase 2 study. In addition, in the phase 3 studies, faricimab showed greater anatomic improvement compared with aflibercept (Eyelea, Regeneron) and potential for improved durability due to vascular stability by Ang-2 inhibition.

Faricimab is the only medicine targeting two distinct pathways, Ang-2 and VEGF-A, that often cause retinal diseases that may cause vision loss.

Related Content: Additional AAO content | Retina | Gene Therapy